Navigation Links
VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
Date:8/4/2009

MOUNTAIN VIEW, Calif., Aug. 4 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Canaccord Adams 29th Annual Global Growth Conference in Boston.

The VIVUS presentation will take place at the Intercontinental Hotel on Thursday, August 13, 2009 at 8:30 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://www.wsw.com/webcast/canaccord/vvus or http://www.vivus.com.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(TM), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(TM), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(R) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

<
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS to Present at the Needham and Company Life Sciences Conference
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS Reports First Quarter 2009 Financial Results and Highlights
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Oncothyreon announces presentation of long-term Stimuvax data at World Conference on Lung Cancer
6. Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
7. Stemline Therapeutics CEO to Present at IBCs New Frontiers in Cancer Drug Development Conference
8. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
9. Patent Awarded for a New X-ray Imaging Technology with Capability Unrealized with Present Day Radiological Modalities
10. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
11. Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... MA (PRWEB) September 02, 2014 ... today the signage of a distribution agreement with ... is now distributing Myriant’s bio-succinic acid in the ... and Ireland, targeting customers in the industrial and ... distribution powerhouse, Azelis offers a far-reaching chemical portfolio ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)... 2014  Spherix Incorporated (SPEX) -- an intellectual property development company ... today announced that the United States Patent & Trademark ... the month of August that are part of a ... issued patents are: , U.S.RE45,065 issued ... 2014; and , U.S.RE45,095 issued August 26, 2014.  ...
(Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
Breaking Biology Technology:Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5
... Mass., Sept. 19 Boston Scientific,Corporation (NYSE: BSX ... Life,Sciences Conference, which is being held September 22 - ... Chief Executive Officer, will make a,30-minute presentation which will ... Thursday, September 25, beginning at approximately 9:00,a.m. ET., ...
... PARK, Ill., Sept. 19 Abbott (NYSE:,ABT) will announce ... before the market opens., The announcement will be ... at 8 a.m. Central time (9 a.m. Eastern), and ... http://www.abbottinvestor.com . An archived edition of the call will ...
... China, Sept. 19 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... Chinese firm specializing in the manufacture,research, development, ... that at its 2008 Annual General Meeting ... the Company,s nominees to the,Board of Directors., ...
Cached Biology Technology:China-Biotics, Inc. Announces Results of 2008 Annual General Meeting of Shareholders 2
(Date:9/2/2014)... distribution of media will have lower carbon emissions ... file sizes are large. , That,s the conclusion ... of Industrial Ecology that looked at the ... PlayStation3. Researchers found that Blu-ray Discs delivered via ... game files downloaded over broadband Internet. For their ...
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor core ... in a single season because of injury than are pitchers ... and pelvis. , In the study, 347 pitchers were assessed ... in their pelvis as they raised a leg to step ... at least 30 days cumulative, not consecutive during ...
(Date:9/2/2014)... new study published in the September issue of ... identifies a novel strategy to diagnose the leading ... irreversible structural damage has occurred. This advance involves ... on the endothelium of retinal vessels. Using new ... distinguish the early molecular development of diabetic retinopathy. ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Molecular probes permit doctors to detect diabetic retinopathy before vision fails 2
... for hundreds of years as an herbal remedy to prevent ... commonly used herbal medicines in North America. However, in spite ... on the body,s immune system are conflicting. ... University Indianapolis are investigating the possibility that Echinacea has other ...
... 20 million people in the U.S., and many more worldwide, ... developing mesothelioma, a malignant cancer of the membranes that cover ... Moreover, asbestos exposure increases the risk of lung cancer among ... understand why asbestos causes cancer. The answer ...
... Tuesday 29 June 2010, announces this year,s award winners ... to theoretical physicist Professor Edward Witten for outstanding, transformative ... influential physicists of the past 30 years, he has ... particle physics and cosmology to theoretical areas of string ...
Cached Biology News:Mystery unraveled: How asbestos causes cancer 2IOP announces 2010 award winners 2
Request Info...
1+ mg expected yield of purified protein, expressed in insect cells - excludes cDNA...
... BioNumerics is the universal bioinformatics software that ... data. The unique modular design of BioNumerics ... virtually any type of data employed for ... microarrays, DNA fingerprints, 2-D protein gels, HPLC, ...
Request Info...
Biology Products: